IMMP

Immutep (IMMP)

About Immutep (IMMP)

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Details

Daily high

$2.76

Daily low

$2.52

Price at open

$2.64

52 Week High

$3.53

52 Week Low

$1.32

Market cap

402.3M

Dividend yield

0.00%

Volume

341,717

Avg. volume

165,882

P/E ratio

-7.38

Immutep News